By Dr. Yahia Anane

When cancer is first diagnosed, it is — in most cases — not yet at its most dangerous point. It has not fully spread. It has not developed resistance. It has not captured your system.

That window immediately after diagnosis is arguably the most critical and most wasted window in oncology.

What you decide to do — or not do — in the weeks and months that follow can either contain cancer or accelerate it into something far harder to address. Most patients are never told this.

The Four Decisions That Turn Cancer Into a Crisis

1. Rushing Into Treatment Without the Full Picture

Panic is the cancer industry’s most reliable tool. The pressure to start chemotherapy within days, schedule surgery before understanding staging, or begin radiation before evaluating alternatives is not always driven by clinical urgency.

Before any intervention, establish a full baseline. Comprehensive blood work — inflammatory markers (CRP, ESR), metabolic indicators (fasting glucose, insulin, HbA1c), immune function (lymphocyte count, LMR), liver and kidney function, and nutrient status (vitamin D, magnesium, zinc, selenium) — tells you what terrain the tumor is operating in. Without it, you are treating blindly.

2. Toxic Treatments Without Understanding the Collateral Damage

Chemotherapy and radiation do not effectively eliminate cancer stem cells (CSCs) — the resistant, metabolically flexible cells that drive recurrence and metastasis. Analysis of chemotherapy’s contribution to 5-year survival rates in Australia and the US found a benefit of only 2.1–2.3%. Up to 80% of cancers recur after conventional treatment, and when they return, they are typically more aggressive.

The collateral damage compounds this: lymphopenia removes immune surveillance; bone marrow suppression drives anemia and intratumoral hypoxia via HIF-1α, which activates glycolysis, angiogenesis, and metastatic programs; gut destruction eliminates the microbiome critical for immune regulation.

If conventional treatment is chosen, protect the host simultaneously: fasting before and after (differential stress resistance), anti-inflammatory support (curcumin, black seed oil, omega-3s), liver protection (TUDCA, milk thistle), and immune rebuilding (vitamin D3, zinc, selenium, medicinal mushrooms, probiotics).

3. Ignoring the Underlying Metabolic Dysfunctions

This is the most common and most costly failure — across both conventional and alternative approaches.

Patients undergo aggressive treatments while maintaining hyperglycemia that directly fuels Warburg-dependent tumors. They remain sedentary, sleep poorly, stay vitamin D deficient, and keep chronic inflammation running — all of which actively reshape the tumor microenvironment in the tumor’s favor.

The dysfunctions that must be corrected:

• Hyperglycemia and insulin resistance → ketogenic diet (<20g carbs/day, GKI target <2), intermittent and prolonged fasting, metformin or berberine to suppress IGF-1/PI3K-AKT-mTOR signaling
• Chronic inflammation → curcumin, omega-3s, black seed oil, low-dose naltrexone (LDN 1–4.5mg) to boost NK cells and reduce TNF-α, IL-6, and NF-κB
• Nutrient deficiencies → vitamin D, magnesium, zinc, selenium, omega-3s — deficiencies in all of these impair immune competence, mitochondrial function, and antioxidant capacity
• Circadian and sleep disruption → melatonin is an oncostatic hormone; chronic sleep disruption suppresses it while elevating cortisol, creating a physiologically pro-tumorigenic state
• Cachexia → exercise, protein-sufficient ketogenic nutrition, omega-3s, and lactoferrin to counteract the IL-6/TNF-α-driven muscle wasting that predicts poor survival

4. Not Making Drastic Lifestyle Changes

Cancer does not arise in a metabolically healthy body. Finishing treatment and returning to the habits that created the conditions for cancer is one of the most biologically self-defeating things a patient can do — yet it is extremely common.

When cancer recurs, the cancer stem cells that survived treatment now operate in an immune-suppressed, inflamed, metabolically permissive environment — the same one that existed before, often worsened by treatment toxicity.

The reconstruction: strict ketogenic or low-glycemic anti-inflammatory diet; regular exercise to mobilize NK cells; stress management to reduce sympathetic-driven immune suppression; sleep and circadian restoration to recover melatonin and normalize cortisol.

The Repurposed Drug Layer

Ivermectin inhibits Wnt/β-catenin and YAP/Hippo signaling — the pathways maintaining cancer stem cell identity — while inducing mitochondrial dysfunction and apoptosis. Fenbendazole disrupts microtubule polymerization, collapses glycolysis, raises ROS, reactivates p53, and targets CSC markers simultaneously. These are not standalone solutions — their power comes from integration into a full metabolic protocol.

Monitor Everything

Strategy without measurement is hope. Blood work tracks whether your protocol is working or damaging you. Rising inflammation, falling lymphocytes, climbing liver enzymes — these are signals to act early, not discover late. If a strategy isn’t improving your markers, change it. Healing is not about belief. It is about data.

Bottom Line

Cancer at diagnosis is a problem with definable metabolic drivers and correctable vulnerabilities. Cancer after a series of uninformed, reactive, metabolically ignorant decisions becomes a crisis — resistant, aggressive, and far harder to reverse.

The difference is not luck. It is knowledge, strategy, and execution.

Fix the metabolism. Protect the immune system. Correct the terrain. Never stop.

Dr. Yahia Anane — Metabolic Cancer Researcher | drananeyahia.com